Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Johns Hopkins

Sites in Baltimore, MD

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 1:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1433
Shown on this page
12
Current sort
Recently updated
Campus scope
Johns Hopkins, Baltimore, MD
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Johns Hopkins, Baltimore, MD. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 889–900 of 1,433 matching trials with a site at Johns Hopkins, Baltimore, MD.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 2 Interventional

Peripheral Modulation of Muscle Stiffness and Spasticity

NCT03306615
Site status not listed — check the official record
View directory record Official record
Conditions
Muscle Spasticity
Interventions
Hyaluronidase, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 31, 2026, 1:25 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes

NCT04802161
Site status not listed — check the official record
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia With Multilineage Dysplasia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
Interventions
Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Liposome-encapsulated Daunorubicin-Cytarabine, Pomalidomide
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
11
States / cities
Atlanta, Georgia • Kansas City, Kansas • Westwood, Kansas + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 31, 2026, 1:25 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Anatomical and Functional Imaging Correlates of Chronic Pain in Cerebral Palsy

NCT05197946
Status at this site: Recruiting
View directory record Official record
Conditions
Cerebral Palsy, Chronic Pain
Interventions
MRI
Diagnostic Test
Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Other
Eligibility
8 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2028
U.S. locations
4
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 31, 2026, 1:25 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder

NCT05452772
Status at this site: Active, not recruiting
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Psilocybin, Niacin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
3
States / cities
Birmingham, Alabama • Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 31, 2026, 1:25 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Cognitive Outcomes After Brain Substructure-informed Radiation Planning in Pediatric Patients

NCT05658731
Status at this site: Recruiting
View directory record Official record
Conditions
Brain Tumor, Head and Neck Cancer
Interventions
substructure informed planning, Neurocognitive Testing, MRI
Radiation · Other · Diagnostic Test
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
1 Year to 26 Years
Enrollment
338 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2035
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 31, 2026, 1:25 AM EDT
Recruiting Phase 2 Interventional

Embryonal Tumor With Multilayered Rosettes

NCT06861244
Status at this site: Recruiting
View directory record Official record
Conditions
Embryonal Tumor With Multilayered Rosettes, Embryonal Tumor With Multilayered Rosettes, Nos
Interventions
Radiotherapy (RT), Chemotherapy Drug, Cancer - Physician's Choice, Non-Investigational Surgical Resection, Temozolomide, Tumor Tissue Sample, Blood Sample, Cerebrospinal Fluid (CSF) Sample
Radiation · Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
Not listed
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
8
States / cities
Birmingham, Alabama • San Francisco, California • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 31, 2026, 1:25 AM EDT
Active, not recruiting Phase 2 Interventional

The PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): A Phase II Study of Breast-Conserving Surgery Without Adjuvant Radiotherapy for Favorable-Risk Breast Cancer

NCT02653755
Site status not listed — check the official record
View directory record Official record
Conditions
Breast Cancer Radiation
Interventions
Prosigna
Device
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
50 Years to 75 Years · Female only
Enrollment
671 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2030
U.S. locations
6
States / cities
Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 31, 2026, 1:25 AM EDT
Active, not recruiting Phase 3 Interventional

To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis

NCT05908084
Site status not listed — check the official record
View directory record Official record
Conditions
End Stage Renal Disease (ESRD)
Interventions
Acellular Tissue Engineered Vessel (ATEV), AVF
Biological · Other
Lead sponsor
Humacyte, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
32
States / cities
Scottsdale, Arizona • El Centro, California • La Jolla, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 31, 2026, 1:25 AM EDT
Recruiting Phase 2 Interventional

Combination Therapy for the Treatment of Diffuse Midline Gliomas

NCT05009992
Status at this site: Recruiting
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent WHO Grade III Glioma, WHO Grade III Glioma
Interventions
ONC201, Radiation Therapy, Paxalisib, DNX-2401
Drug · Radiation
Lead sponsor
University of California, San Francisco
Other
Eligibility
2 Years to 39 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 31, 2026, 1:25 AM EDT
Recruiting Not applicable Interventional

Testing the Impact of Smartphone-based Messaging to Support Young Adult Smoking Cessation

NCT05836103
Status at this site: Recruiting
View directory record Official record
Conditions
Tobacco Cigarette Smoking
Interventions
Smartphone-based intervention messages
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 30 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 31, 2026, 1:25 AM EDT
Active, not recruiting Phase 2 Interventional

Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM)

NCT05120284
Site status not listed — check the official record
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Dichloroacetate (DCA), Genotype
Drug · Genetic
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Baltimore, Maryland • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 31, 2026, 1:25 AM EDT
Recruiting Phase 2 Interventional

Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease

NCT05650229
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Primary Mitochondrial Disease
Interventions
KL1333, Placebo
Drug
Lead sponsor
Pharming Technologies B.V.
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
20
States / cities
Orange, California • San Diego, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 31, 2026, 1:25 AM EDT

About this Johns Hopkins institution page

What this page lists
ClinicalTrials.gov records that list Johns Hopkins in Baltimore, MD as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.